Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KY 1005

Next Previous
Drug Profile

KY 1005

Alternative Names: KY1005

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Autoimmune disorders
  • No development reported Graft-versus-host disease

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for preclinical development in Graft-versus-host-disease in United Kingdom (Parenteral)
  • 13 Dec 2018 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly) in Germany (IV) (NCT03754309)
  • 30 Nov 2018 Kymab plans a phase II trial for Atopic dermatitis in Germany, Poland, Spain, and in the UK (NCT03754309)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top